ArticlePediatric cardiology2011
High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias.
Article in Pediatric cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05418036 (Safety Assessment for Sotalol Protocol in Outpatient Unit), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety Assessment for Sotalol Protocol in Outpatient Unit
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Severe Hypoglycemia Associated With Oral Sotalol Use in Two Children.HeartRhythm case reports · 2021Article
- Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre.BMC cardiovascular disorders · 2021Observational
- Intravenous Amiodarone and Sotalol Impair Contractility and Cardiac Output, but Procainamide Does Not: A Langendorff Study.Journal of cardiovascular pharmacology and therapeutics · 2019Article
- Early experience with intravenous sotalol in children with and without congenital heart disease.Heart rhythm · 2018Article
- Intravenous sotalol for conversion of atrial flutter in infants.HeartRhythm case reports · 2018Article
- Neonatal arrhythmias: diagnosis, treatment, and clinical outcome.Korean journal of pediatrics · 2017Review
- Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia.Pediatric cardiology · 2017Article
- Variation in Antiarrhythmic Management of Infants Hospitalized with Supraventricular Tachycardia: A Multi-Institutional Analysis.Pediatric cardiology · 2016Article
- Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database.Early human development · 2015Article
- Factors associated with the occurrence and treatment of supraventricular tachycardia in a pediatric congenital heart disease cohort.Pediatric cardiology · 2014Article
- Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal.Journal of atrial fibrillationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our objective was to assess the efficacy and safety of high-dose sotalol in neonates and infants with refractory supraventricular tachycardia (SVT). SVT in neonates and infants can be refractory to primary therapies; therefore, secondary agents, e.g., sotalol, are often required to obtain control of SVT. Age-factor nomogram dosing of sotalol is widely used; however, our institution uses greater doses based on body surface area (approximately 150-200 mg/m(2)/d). A retrospective review of 78 inpatients receiving sotalol, after failing another antiarrthymic medication, at our institution from 2001 to 2008 was performed. Corrected QT intervals (QTc), 24-h Holter-monitoring results, and outpatient records were reviewed to assess safety and efficacy for patients ≤ 2 years of age. Median patient age at the time of initiation of therapy was 24 days (range 3-728). Forty-eight patients (62%) were neonates, and 36 (46%) had congenital heart disease. The median sotalol dosage was 152 mg/m(2)/day (range 65-244). The SVT of 70 patients (90%) was controlled with sotalol. No patients experienced significant QTc prolongation or proarrhythmia. Mean duration of follow-up was 3.3 ± 0.24 years. High-dose sotalol allows for safe and rapid control of refractory tachyarrhythmias in this young age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.